Gestational diabetes mellitus (GDM) is a common obstetric complication. Half of women who have GDM will go on to develop type 2 diabetes. Understanding the mechanisms by which this occurs requires an animal model of GDM without ongoing diabetes at conception. C57Bl/6J mice react acutely to a high-fat, high-sucrose (HFHS) challenge. Here, we hypothesized that a periconceptional HFHS challenge will induce glucose intolerance during gestation. C57Bl/6J female mice were placed on an HFHS either 1 or 3 weeks prior to mating and throughout pregnancy. Intraperitoneal glucose tolerance tests, insulin measurements, and histological analysis of pancreatic islets were used to assess the impact of acute HFHS. C57Bl/6J females fed HFHS beginning 1 week prior to pregnancy became severely glucose intolerant, with reduced insulin response to glucose, and decreased pancreatic islet expansion during pregnancy compared to control mice. These GDM characteristics did not occur when the HFHS diet was started 3 weeks prior to mating, suggesting the importance of acute metabolic stress. Additionally, HFHS feeding resulted in only mild insulin resistance in nonpregnant females. When the diet was discontinued at parturition, symptoms resolved within 3 weeks. However, mice that experienced glucose intolerance in pregnancy became glucose intolerant more readily in response to a HFHS challenge later in life than congenic females that experienced a normal pregnancy, or that were fed the same diet outside of pregnancy. Thus, acute HFHS challenge in C57Bl/6 mice results in a novel, nonobese, animal model that recapitulates the long-term risk of developing type 2 diabetes following GDM. A. Pennington et al., 2017, Vol. 96, No. 2 
Introduction
Gestational diabetes mellitus (GDM), broadly defined as the diagnosis of diabetes during pregnancy [1, 2] , is one of the most prevalent obstetric complications, affecting up to 18% of women depending on demographics and diagnostic criteria [1] [2] [3] . Diagnosis of GDM is based on elevated blood glucose levels identified during a standard oral glucose tolerance test, traditionally given between 24 and 28 weeks of pregnancy [2] . Although GDM usually resolves after pregnancy, it is associated with lasting health effects in mother and baby [1, 4] . These include a 60% greater risk for developing type 2 diabetes within 5-16 years of a pregnancy complicated by GDM compared to an uncomplicated one [5, 6] . It is not known whether women who develop GDM are simply already predisposed to type 2 diabetes, or whether damage induced by GDM directly increases the risk of type 2 diabetes in later life.
Pregnancy is a natural state of insulin resistance [4, 7] . To compensate for this, beta cell mass expands and insulin secretion in response to glucose is increased compared to a nonpregnant state [8] [9] [10] [11] . In rodents, beta cells both hypertrophy and proliferate between the time of implantation and days 15 and 16, with beta cell mass peaking near term, and then returning to baseline within 2 weeks of parturition, with the onset of beta cell apoptosis [11, 12] . Women with GDM have greater insulin resistance [13] [14] [15] coupled with an inadequate beta cell response [7, [16] [17] [18] [19] . For example, in a trial of 175 women, insulin response to oral glucose administration was reduced by 34% in women with GDM, and by 67% when adjusted for insulin sensitivity [20] . A postmortem case report is consistent with the hypothesis of inadequate beta cell expansion in GDM [21] , as are data from knockout mouse models in which beta cell expansion is impaired [22] [23] [24] . However, the pathophysiology of GDM is not completely understood.
The pathogenesis of GDM has increasingly been linked to lipotoxicity [25] . Numerous studies have implicated lipotoxicity in the development of type 2 diabetes [26] . GDM is also associated with dyslipidemia, including elevated serum triglyceride and leptin concentrations [27] [28] [29] [30] . Prentice et al. found that 25 lipid species are elevated in serum from women with GDM, and that the most elevated, the furan fatty acid 3-carboxy-4-methyl-5-propyl-2-furanoprpanoate (CMPF), is sufficient to cause beta cell dysfunction upon injection into mice [31] .
The C57Bl/6J mouse is particularly susceptible to the effects of high-fat diet on obesity and insulin resistance [32] . High-fat, highsucrose (HFHS) diet feeding in these mice induces an acute response less than a week after initiation of feeding, including insulin resistance, glucose intolerance, and inflammation, followed by a period of adaptation during which no impairments in glucose tolerance or insulin are observed [32] . We hypothesized that if the acute response to high-fat diet were to coincide with the beta cell remodeling of pregnancy, it would interfere with islet expansion, leading to glucose intolerance of pregnancy. Mice with a mutation in one copy of the leptin receptor gene (Lepr db/+ ) have previously been shown to develop glucose intolerance when fed HFHS beginning just prior to pregnancy [33] . Here, we test whether glucose tolerance diminishes similarly in pregnant wild-type (WT) C57Bl/6J mice following an acute HFHS challenge, whether glucose intolerance is limited to gestation, and whether it is associated with impaired beta cell proliferation. Finally, we used this mouse model to test whether experiencing glucose intolerance in pregnancy increases susceptibility to insulin resistance in later life, even compared to mice with the same genetics and same dietary history.
Materials and methods

Animal handling and procedures
All animal procedures were approved by the University of Missouri and Baylor College of Medicine Animal Care and Use Committee and performed in accordance with the NIH Guide for the Care and Use of Laboratory Animals. An overview of the study design is presented in Figure 1 . Experiment 1: Seven-week-old female WT C57BL/6J and Lepr db/+ mice (B6.BKS(D)-Lepr db /J strain 000697) were purchased from JAX R (Bar Harbor, ME). Mice of each genotype were allocated to one of three diet groups: (1)CD, control diet (LabDiet 5008, Purina, St. Louis, MO) (n = 8 WT CD; n = 4 Db/+); (2)4HFHS, high-fat and high-sucrose diet (D12451, Research Diets Inc., New Brunswick, NJ) for 1 week prior to mating and throughout 3 weeks of pregnancy (n = 9 WT 4HFHS; n = 6 Db/+), or (3)6HFHS, high-fat and high-sucrose diet 3 weeks prior to mating and throughout pregnancy (n = 7 WT; n = 3 Db/+). HFHS contained 45% kcal/fat, 17% kcal/sucrose, and CD was 17% kcal/fat, 2.4% kcal/sucrose. Females were mated to proven breeder WT C57Bl/6J males. At gestational day 17.5, dams were fasted for 4 h and blood was collected for fasting serum insulin determination. Then intraperitoneal glucose tolerance tests (IPGTT) were performed as previously described [34] , but with duplicate measurements made using two ReliOn Prime Blood Glucose Monitoring System meters (Walmart, Bentonville, AR). Following IPGTT, dams were sacrificed. Blood and tissues were collected for further analysis (Figure 2A ).
Experiment 2: Seven-week-old female WT C57BL.6J were placed on CD (n = 7) or HFHS for 1 (n = 7, 4HFHS) or 3 (n = 7, 6HFHS) weeks, at which time they were fasted for 4 h and subjected to IPGTT. This was done to examine glucose tolerance at the time just prior to mating. Animals were then sacrificed and blood and tissues were collected for further analysis ( Figure 3A) .
Experiment 3: Seven-week-old female WT C57BL/6J were placed on CD or HFHS beginning 1 week prior to mating (4HFHS). At day 17.5, an IPGTT was performed after a 4 h fast, and blood was collected at each time point for evaluation of insulin release. Not all blood collections during IPGTT yielded enough serum for insulin measurement, so n is indicated for each time in the results below. Insulin sensitivity was estimated by QUICKI, an insulin sensitivity index developed in humans [35] , which also has been verified to correspond to insulin sensitivity in mice [36] and pregnant rats [37] . It was calculated using the following formula: QUICKI = 1/[log(I 0 ) + log(G 0 )], where I 0 is fasting insulin (μU/ml) and G 0 is fasting glucose (mg/dl). At sacrifice, fetal and placental weights were recorded and placental efficiency was calculated by dividing fetal by placental weight (Figure 2A ). Experiment 4: Seven-week-old female WT C57BL/6J were placed on CD (n = 8) or HFHS (n = 9) beginning 1 week prior to mating. At day 13.5, an IPGTT was performed after 4 h fasting, at the conclusion of which animals were sacrificed, fetal and placental weights were recorded, and placental efficiency was calculated ( Figure 5A ). Blood and tissue samples were collected for further analysis.
Experiment 5:
Seven-week-old female WT C57BL/6J were randomly allocated to a pregnant or nonpregnant (V, virgin) group, and each of these were assigned to CD or HFHS (n = 4 P CD; n = 7 P 4HFHS; n = 8 V CD; n = 8 V 4HFHS). IPGTT was performed following 4 h fasting, after 1 week of diet treatment, just prior to mating in P. At gestational day 17.5, fasting glucose was assessed in the P group. At the same time, 4 weeks after initiation of diets, V mice were subjected to IPGTT, and fasting insulin was measured. All mice were returned to CD when P mice delivered pups. IPGTTs were performed 3 weeks later at the time that P were weaned ( Figure 6A ). Animals from all four treatment groups were maintained on CD for another 4 weeks and then challenged with HFHS for 6 weeks, at which time IPGTT was performed ( Figure 7A ). Animals were then sacrificed, and blood and tissue samples were collected for further analysis. As there was not sufficient serum volume to perform every analysis for every mouse, sample sizes for each analysis are noted in the figure ( Figure 7 ).
Hormone analysis
Serum leptin and insulin were measured using a Mouse Leptin ELISA (EMD Millipore, Billerica, MA) and a Rat/Mouse Insulin ELISA (EMD Millipore) according to the manufacturer's instructions. Intraassay coefficients of variation were 5.66 ± 0.62% and 7.33 ± 0.82% and interassay CVs were 5.71 ± 1.18% and 8.11 ± 2.07% for insulin and leptin ELISAs, respectively. Serum IL-6 levels were measured using a Mouse IL-6 ELISA Kit (Sigma-Aldrich, St. Louis, MO) according to the manufacturer's instructions. Intraassay CV was <10% and interassay CV was <12%.
Triglycerides
Serum triglyceride levels were measured using the Serum Triglyceride Determination Kit (Sigma-Aldrich). Triglycerides were extracted from liver samples using a modified Folch protocol, as previously described [38, 39] and then quantified using the same Serum Triglyceride Determination Kit.
Pancreatic morphology
Immunohistochemistry was performed on day 17.5 pancreatic tissue to compare alpha and beta cell numbers as previously described [34, [40] [41] [42] [43] . Briefly, pancreata were fixed in 4% paraformaldehyde, embedded in paraffin, and 5 μm sections were cut at 100 μm intervals. Following blocking in 10% normal goat serum, sections were stained overnight at 4
• C for glucagon (K79bB10, Abcam Inc., Cambridge, MA) and insulin (ab63820, Abcam Inc.) at 1:2000 and 1:1000 dilutions, respectively. AlexaFlour 568 goat anti-mouse IgG (Invitrogen, Carlsbad, CA) and AlexaFlour 488 goat anti-rabbit IgG were used for detection at 1:500 dilutions. Alpha and beta cell numbers were manually counted in each pancreatic islet using ImageJ software (NIH) by an operator blinded to treatment group. At least 12 islets, sampled randomly from six independent tissue sections, were assessed to estimate the average beta cell and alpha cell numbers per islet for each mouse.
Statistical analysis
IPGTT data were analyzed using two-way ANOVA with diet and time as factors using GraphPad Prism (La Jolla, CA), which was also used to calculate area under the curve (AUC) for each test. Generalized linear model (GLM) with least square means (LSM) was used to analyze experiment 1 weights, AUC, leptin, and insulin data with genotype and diet as factors in Statistical Analysis System software (SAS R , SAS institute, Cary, NC). Beta cell numbers were analyzed by the Mann-Whitney test in Prism, as data were not normally distributed according to the Kolmogorov-Smirnov test. Postpartum insulin and leptin data were analyzed using GLM with previous pregnancy status and diet as factors and LSM for post hoc pairwise comparisons in SAS R . For other experiments, data were analyzed using a 1-way ANOVA or Student's t-test in Prism.
Results
Gestational glucose tolerance in dams fed high-fat and high-sucrose beginning 1 or 3 weeks prior to mating Mice were fed an HFHS diet beginning 1 week or 3 weeks prior to gestation and then assessed at gestation day 17.5, for a total of 4 (4HFHS) or 6 (6HFHS) weeks of HFHS feeding (Figure 2A ). Lepr db/+ dams on the 4HFHS diet were glucose intolerant ( Figure 2B and C), consistent with previous reporting, though if only incremental glucose values were considered, the diet response was not significant (Supplemental Figure S1A) . Glucose intolerance was also apparent in WT C57Bl/6J mice fed 4HFHS ( Figure 2D and E, Supplemental Figure S1B ). In contrast, glucose tolerance at day 17.5 was not significantly impaired in 6HFHS dams, regardless of genotype, though only three Lepr db/+ mice were assessed ( Figure 2B -E, Supplemental Figure S1A and B) Fasting serum insulin was significantly reduced in 4HFHS and 6HFHS versus CD dams within each genotype ( Figure 2F ), and was lower in WT than Lepr db/+ dams. There was also a significant interaction (P < 0.05) between diet and dam genotype, with a more significant decrease in serum insulin in response to HFHS diet in Lepr db/+ compared to WT dams. Serum insulin at 120 minutes postglucose injection was significantly reduced in 4HFHS and 6HFHS versus CD in WT but not Lepr db/+ dams ( Figure 2G ).
Serum leptin was significantly increased in 4HFHS compared to 6HFHS and CD mice regardless of genotype ( Figure 2H ). Maternal weights were not affected by HFHS, although Lepr db/+ dams were significantly heavier than WT dams ( Figure 2I ). Because WT and Lepr db/+ dams responded similarly to the HFHS diet, only WT mice were used in subsequent experiments.
Glucose tolerance in female mice following 1 or 3 weeks of high-fat and high-sucrose feeding
Glucose tolerance was next assessed under the 4HFHS and 6HFHS treatments just prior to mating, i.e. after 1 (4HFHS) or 3 (6HFHS) weeks of HFHS feeding ( Figure 3A) , to determine the time of diabetes onset in the 4HFHS group, and to identify potential differences among groups prior to conception. There was a slight reduction in glucose tolerance in mice fed HFHS for 3 weeks prior to mating (6HFHS), with glucose concentrations significantly higher than controls at 15 and 30 min, though AUC was not significantly different (P = 0.07) ( Figure 3B and C). There were no differences in incremental glucose concentrations (Supplemental Figure S1C ). Glucose tolerance was not different from CD in mice that had begun HFHS 1 week prior (4HFHS). However, there was an indication (P = 0.07) of increased insulin concentrations in 4HFHS but not 6HFHS mice at 120 min post-glucose injection ( Figure 3D ). In summary, at the time of mating, the 4HFHS
were not yet glucose intolerant or insulin deficient, but showed some evidence of insulin resistance. Serum leptin levels were significantly increased in 6HFHS compared to CD dams, but were not different in 4HFHS dams ( Figure 3E ). Weights at day 0 were not different (data not shown). Serum and liver triglycerides were also not different at day 0 ( Figure 2F ). Serum IL-6, a marker of inflammation, was below the limits of detection in most samples from all treatment groups (data not shown).
High-fat and high-sucrose feeding for 1 week prior to and during pregnancy impairs beta cell expansion
To determine the cause of decreased fasting and 120 min postglucose injection insulin levels in 4HFHS and 6HFHS dams, pancreatic alpha and beta cell numbers were examined (representative images, Figure 4A -C) at day 17.5 of pregnancy. There were significantly fewer beta cells in 4HFHS ( Figure 4D ) compared to CD dams, and some evidence of reduced alpha cell numbers ( Figure 4E , P = 0.11), indicating that beta cell expansion of pregnancy, and perhaps islet expansion generally, was impaired in 4HFHS dams. However, no differences in beta or alpha cell numbers were observed in 6HFHS dams compared to control or 4HFHS dams, indicating 6HFHS dams were able to undergo normal beta cell expansion and may be one reason glucose intolerance was not observed in these animals.
Because only 4HFHS mice displayed impaired glucose tolerance during gestation, the 6HFHS treatment group was not used in subsequent experiments. Next we sought to determine if lower beta cell numbers resulted in reduced insulin release in response to glucose. To test this, IPGTT was again performed at day 17.5 in 4HFHS and CD dams, but with serum insulin values assessed at each time point. The 4HFHS dams again displayed significantly reduced glucose tolerance at day 17.5 ( Figure 4F and G, Supplemental Figure S1D ). Insulin concentrations were lower in 4HFHS throughout the IPGTT (Figure 4H and I) . The QUICKI index of insulin sensitivity was not different between CD (0.31 ± 0.01) and 4HFHS (0.33 ± 0.005).
Liver and serum triglycerides were assessed to determine whether either was associated with the diet-induced glucose intolerance. Although serum triglyceride concentrations were not significantly different, liver triglyceride content was elevated in 4HFHS dams, after just 4 weeks of HFHS diet ( Figure 4J and K) . The 4HFHS did not alter pregnancy characteristics assessed at day 17.5. No differences occurred in litter size, fetal or placental weights, or placental efficiency between CD and 4HFHS mothers (Supplemental Table S1 ).
Glucose intolerance and insulin deficiency arise by mid-pregnancy with 4HFHS diet
In women, GDM screening is performed at the mid-late second trimester. Therefore, 4HFHS mice were next examined at day 13.5, two-thirds of the way through gestation ( Figure 5A ). As at day 17.5, the 4HFHS dams showed glucose intolerance at day 13.5, with significantly elevated AUC, although unlike at day 17.5, blood glucose concentrations returned to baseline at 120 min postinjection ( Figure 5B and C, Supplemental Figure S1E ). Insulin concentrations were significantly reduced at 120 min ( Figure 5D ). Similarly, the failure of islet expansion was already apparent by day 13.5 in the 4HFHS dams, with significantly reduced beta and alpha cell numbers compared to pregnant controls ( Figure 5E-I) . Serum leptin levels were not different between CD and 4HFHS at day 13.5 ( Figure 5G ). No differences were observed between dam weights (data not shown). No differences were observed in litter size, fetal or placental weights, or placental efficiency (Supplemental Table  S1 ). Thus, glucose intolerance and beta cell impairment arise by the second trimester in mice fed HFHS from 1 week before mating.
Glucose intolerance is specific to pregnancy
Next, the effect of 4HFHS feeding was compared in pregnant and nonpregnant mice ( Figure 6A ). Glucose tolerance was assessed in the virgin mice 4 weeks after initiation of the HFHS diet, the same length of time as pregnant mice fed HFHS from -1 week through day 17.5 of gestation. Virgin (V) 4HFHS had slightly impaired glucose tolerance compared to V CD ( Figure 6C and D, Supplemental Figure S1F ). Virgin 4HFHS also had significantly increased fasting insulin concentrations compared to V CD ( Figure 6E ). Of note, fasting insulin concentrations in V 4HFHS were similar to those observed in 4HFHS on pregnancy day 17.5. Thus, insulin secretion in response to glucose increases in CD mice from the nonpregnant state to pregnancy day 17.5, but does not increase with pregnancy in the 4HFHS mice.
Both the pregnant/parous (P) and V CD and 4HFHS mice were placed on CD immediately following delivery by the P mice ( Figure 6A ). Three weeks later, when P mice were weaned, IPGTT was performed in all groups. At this time, in V 4HFHS, there was no difference in glucose tolerance when absolute values were considered ( Figure 6E and F) , though a slight intolerance remained in incremental glucose concentrations (Supplemental Figure S1G) . There was no difference in glucose intolerance when absolute values were considered ( Figure 6G and H), but P 4HFHS animals had significantly elevated incremental glucose concentrations at 15 min (P < 0.05, Supplemental Figure S1H ). At the time of weaning, weights were not significantly different between formerly CD and 4HFHS fed animals, regardless of whether they had experienced a pregnancy (Supplemental Table S1 ), although P females weighed more than V females (22.6 ± 0.5g vs 19.1 ± 0.3g, P < 0.0001). Thus, 4HFHS impairs glucose intolerance only during gestation, and it resolves following gestation with cessation of the HFHS diet.
Dams with gestational diabetes mellitus symptoms show increased risk of glucose intolerance later in life
Females from all four treatment groups (P CD, P 4HFHS, NP CD, NP HFHS) were continued on CD for a total of 7 weeks from the time of parturition ( Figure 7A ). Then all were challenged with HFHS to test whether previous GDM pregnancy would exacerbate or hasten the progression of glucose intolerance. Previous exposure to HFHS had no effect on glucose tolerance in virgin mice (V CD vs V 4HFHS; Figure 7B , Supplemental Figure S1I ). In contrast, females that had previously experienced glucose intolerance and impaired insulin secretion during pregnancy (P 4HFHS) had reduced glucose tolerance compared to females that had experienced a normal pregnancy (P CD), as indicated by significantly higher blood glucose at 30 min postinjection ( Figure 7C , Supplemental Figure S1J ). Weights did not differ with previous diet exposure, or previous pregnancy (Supplemental Table S1 ). Fasting insulin did not differ by previous diet exposure in the V or P groups ( Figure 7D ). Among the CD groups, P females had significantly decreased (P < 0.05) serum leptin levels compared to NP females ( Figure 7E ). This decrease was attenuated in 4HFHS animals, in which pregnancy had been complicated by GDM ( Figure 7E ). Serum triglyceride levels were also significantly decreased (P < 0.05) in P-CD compared to NP-CD ( Figure 7F ). This decrease in triglycerides did not occur in the 4HFHS mice, in which serum triglycerides were significantly elevated compared to P-CD (P < 0.05, Figure 6F ).
Discussion
Here we report that exposure to HFHS just before and during pregnancy in mice can induce symptoms similar to those observed in women with GDM including glucose intolerance, impaired insulin secretion, and impaired beta cell remodeling; without glucose intolerance prior to pregnancy; and with resolution of symptoms following parturition [1, 4] . The same dietary treatment (HFHS for 4 weeks) resulted in only mild insulin resistance when given to nonpregnant mice. These findings are consistent with the hypothesis that acute exposure to HFHS at a critical period of pregnancy can impair islet cell proliferation, leading to glucose intolerance during pregnancy. To our knowledge, this study is also the first demonstration that diabetes symptoms during pregnancy can cause animals to more readily develop glucose intolerance later in life, even compared to animals with the same genetic predisposition and the same dietary history (V 4HFHS). The 4HFHS model therefore will be useful for uncovering the mechanisms by which a pregnancy complicated by glucose intolerance leads to negative long-term maternal health outcomes.
Several studies have used Lepr db/+ mice as a model of spontaneous GDM [44] [45] [46] , whereas others have reported no differences in glucose tolerance or insulin concentrations in these mice [33, 47, 48] . In this study, Lepr db/+ fed a CD were not glucose intolerant. Genetic background may underlie the differing results. Lepr db/+ were used on a C57BL/6 background, whereas the C57BLKS/J strain was used in most previous studies [46] . The lepr db/db phenotype is strain dependent, with continuing hyperinsulinemia in BL/6, but eventual pancreatic failure in BLKS/J [49] . Additionally, commercially available Lepr db/+ have historically carried the db mutation from one parent and the Dock 7m , "misty" mutation from the other to facilitate genotyping [50] . Misty has since been implicated in regulation of body weight and fat accumulation, which could make "control" littermates of Lepr db/+ small and hypoglycemic [51, 52] .
Therefore, we used Lepr db/+ and control mice without misty, which are supplied on the B6 background. Unexpectedly, we found that the brief HFHS reported to induce glucose intolerance in Lepr db/+ mice by Harrod et al. is equally effective in WT mice. Mice exposed to acute HFHS had fewer beta cells than control pregnant mice on days 13.5 and 17.5 of gestation. This could be due to impaired proliferation, increased apoptosis, or both. In normal rat pregnancy, beta cell numbers begin to increase around day 10 of gestation, peaking between days 15 and 18, and likewise increase between days 0 and 15 in the mouse [22, 53] . The expansion of beta cell mass results from both cell proliferation and hypertrophy and transcript levels of antiapototic gene Birc5 are increased, suggesting that inhibition of apoptosis also contributes [11, 12, [54] [55] [56] . In the development of type 2 diabetes, exposure to obesity and obesogenic diet initially leads to beta cell expansion, but eventually causes beta cell apoptosis [57] . In nonpregnant mice, beta cell proliferation begins by one 1 after beginning a high-fat diet which can compensate for insulin resistance for several months, or indefinitely in some individuals [58] [59] [60] [61] . Here, we found that dams exposed to HFHS for a total of 6 weeks, 3 weeks prior to pregnancy and 3 weeks during, had similar beta cell numbers to controls at day 17.5. This observation may be in part due to beta cell proliferation prior to pregnancy, in reaction to the HFHS exposure, and likely explains why 6HFHS dams did not have the same glucose intolerance as 4HFHS dams at mid-pregnancy.
Liver triglyceride accumulation, a key player in the pathogenesis of type 2 diabetes [62] , was significantly elevated in 4HFHS mice at day 17.5. Leptin resistance also contributes to the pathogenesis of type 2 diabetes, and as discussed above, genetic leptin resistance (Lepr db/+ ) can at least contribute to GDM in mice [63] .
Leptin resistance was observed in 4HFHS mice at day 17.5, but not day 13.5 making it unlikely that leptin resistance caused the glucose intolerance and impaired islet remodeling that were already present by 13.5. A number of hormones including prolactin, placental lactogens, vascular endothelial growth factor, and insulin have been implicated in beta cell expansion [22, 53] . The role of these hormones in 4HFHS-impaired expansion should be explored in future studies. C57Bl/6J mice fed a high-fat or HFHS diet for an extended period are a widely used model of obesity and both type 2 and gestational diabetes. Diet-induced obesity symptoms gradually develop, including insulin resistance, glucose intolerance, and chronic inflammatory responses [32] . Depending on precise timing and diet composition, the extended HFHS feeding model mimics either fetal macrosomia or growth restriction, both of which are observed in obesity, while human GDM is typically only associated with macrosomia [64, 65] . Furthermore, this model effectively phenocopies the effects of GDM exposure on adult outcomes in exposed offspring, including obesity and insulin resistance. In mice fed HFHS for an extended period prior to pregnancy, exposure to insulin resistance and glucose intolerance occurs during oocyte development and the periconceptional period as well as during gestation, and which contributes to offspring phenotypes [65] . This is supported by embryo transfer experiments, in which offspring were exposed to the obese dam environment either before or after implantation, or both [66] . The 4HFHS model, in which the dam becomes glucose intolerant only after conception, and which is not complicated by maternal obesity, can complement studies in the extended HFHS model to identify critical periods of exposure, and distinguish between effects of diet and maternal obesity on offspring. This is important as 28%-32% of GDM occurs in women with a normal BMI [67] [68] [69] , and in many cases of GDM, glucose intolerance is not present at conception. One important way in which the 4HFHS dams differ from women with GDM is the absence of significant insulin resistance during pregnancy, as determined from fasting insulin and glucose concentrations (QUICKI) [70] . An insulin tolerance test or euglycemichyperinsulinemic clamp would be needed to understand insulin sensitivity in 4HFHS in greater depth. However, it is clear that 4HFHS glucose intolerance is largely a result of impaired insulin production rather than resistance, and better models this aspect of GDM.
Perhaps the most useful quality of the 4HFHS treatment is its potential for studying the long-term maternal health consequences of experiencing glucose intolerance in pregnancy. While there is a clear association between having a pregnancy complicated by gestational diabetes and risk of developing type 2 diabetes, the nature of this relationship is not known. The association may exist because GDM directly increases the risk of type 2 diabetes, or because shared risk factors underlie both GDM and type 2 diabetes. In women, it is not possible to test directly whether the association is causal, as women cannot be randomized to a normal or GDM pregnancy. This is possible in an animal model. Mice can be randomized to gestational glucose intolerance (P 4HFHS), HFHS diet only (V 4HFHS), or pregnancy only (P CD).
When exposed to a high-fat challenge later in life, P 4HFHS developed glucose intolerance more rapidly than C57Bl/6 that had experienced a normal pregnancy (P CD), or that that been exposed to 4 weeks of HFHS feeding, but had not been pregnant (V 4HFHS). Interestingly, it was the 30 min post-glucose time that was first affected, consistent with observations of impaired first-phase insulin secretion in women with a history of GDM [15, 16] . It is not yet known whether continued HFHS challenge will exacerbate or attenuate differences between 4HFHS and other mice, or whether they would eventually develop symptoms postpartum even without further HFHS challenge. Finally, further investigation will be needed to understand the mechanisms by which 4HFHS exposure during pregnancy leads to postpartum glucose intolerance. The 4HFHS could be treated during pregnancy with insulin or insulin sensitizers to test whether addressing their glucose intolerance could prevent postpartum intolerance, or whether it is the initial pancreatic remodeling failure that leads to long-term consequences.
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